Home › Funds › Royalty Pharma Sub-Manager, LLC › ZBIO
Royalty Pharma Sub-Manager, LLC position in ZBIO
ZENAS BIOPHARMA INC · Health Care
Royalty Pharma Sub-Manager, LLC reported holding 2,388,150 shares of ZBIO (ZENAS BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$64.4M, representing 32.82% of its reported portfolio and ranking #2 among its reported holdings. Royalty Pharma Sub-Manager, LLC has disclosed ZBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Royalty Pharma Sub-Manager, LLC's ZBIO position evolved
Royalty Pharma Sub-Manager, LLC first disclosed a stake in ZBIO in Q4 2025 at 1,263,150 shares (US$45.9M). The position peaked in Q3 2026 at 2,388,150 shares, worth US$64.4M. Across 4 filings, Royalty Pharma Sub-Manager, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,388,150 shares valued at US$64.4M. Notable position changes include a 89% increase in Q1 2026 (shares rose 30% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.26M | $45.86M | New |
| Q1 2026 | 2.39M | $46.69M | Add |
| Q2 2026 | 2.39M | $60.61M | Hold |
| Q3 2026 | 2.39M | $64.41M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZBIO and 13F data
ZBIO (ZENAS BIOPHARMA INC) is a Health Care company. 63 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), Enavate Sciences GP, LLC (US$99.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZBIO
- SR ONE CAPITAL MANAGEMENT, LP 5.04M sh · $127.86M · Q2 2026
- NEA Management Company, LLC 4.02M sh · $102.11M · Q2 2026
- Enavate Sciences GP, LLC 3.92M sh · $99.47M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M sh · $80.32M · Q2 2026
- Fairmount Funds Management LLC 2.36M sh · $59.87M · Q2 2026
- NVP Associates, LLC 1.84M sh · $49.58M · Q3 2026
- Context Capital Management, LLC 31.05M sh · $39.70M · Q3 2026
- EcoR1 Capital, LLC 789.50K sh · $20.04M · Q2 2026
- ArrowMark Colorado Holdings LLC 573.32K sh · $14.55M · Q2 2026
- Rock Springs Capital Management LP 502.08K sh · $12.74M · Q2 2026
- NEXTBio Capital Management LP 426.74K sh · $11.51M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 334.06K sh · $9.01M · Q3 2026
More on Royalty Pharma Sub-Manager, LLC
FAQ
How long has Royalty Pharma Sub-Manager, LLC held ZBIO?
Royalty Pharma Sub-Manager, LLC has disclosed ZBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Royalty Pharma Sub-Manager, LLC's current position in ZBIO?
As of Q3 2026, Royalty Pharma Sub-Manager, LLC holds 2.39M shares of ZBIO (ZENAS BIOPHARMA INC), valued at $64.41M, representing 32.82% of its reported portfolio and ranking #2.
Has Royalty Pharma Sub-Manager, LLC been buying or selling ZBIO?
In the latest 13F filing (Q3 2026), Royalty Pharma Sub-Manager, LLC held unchanged its position in ZBIO. The position peaked in Q3 2026 at 2.39M shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, among 63 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.